Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanotechnology Startup AeonClad Coatings, LLC, Licenses Plasma Deposition Technology from The University of Texas at Arlington

Abstract:
AeonClad's New Method is a Breakthrough in Nanotechnology Coatings

Nanotechnology Startup AeonClad Coatings, LLC, Licenses Plasma Deposition Technology from The University of Texas at Arlington

Austin, TX | Posted on July 9th, 2007

AeonClad Coatings, LLC ( http://www.aeonclad.com ), announced today that it has obtained an exclusive license from The University of Texas at Arlington for a plasma coating technology for medical and industrial applications. AeonClad, an Emergent Technologies Fund IV portfolio company, is headed by Dr. Richard Timmons, Chief Scientist, and Tony Taylor, Managing Director.

AeonClad's advanced plasma deposition technology is a new method for coating nanoparticles and devices, with the ability to custom-design the molecular surface to suit the environment in which it will be used. Applications of the technology include improved biocompatibility of medical implants and enhanced functionality of coated particles for laboratory and industrial purification processes.

"The plasma deposition process starts with a monomer gas and then efficiently deposits thin polymeric films to any nearby surface," Dr. Timmons commented. "The variable duty cycle pulsed plasma we have developed provides excellent compositional control of the coatings."

AeonClad's proprietary pulsing algorithm is a significant improvement over existing plasma deposition methods because it maximizes surface deposition rates and minimizes surface ablation. "This new method is a breakthrough in nanotechnology coatings since it allows for ultra-thin, highly controllable, functional surfaces with no ‘pin-holes' that inhibit a device's intended function," added Timmons.

Key Markets and Business Development

Key market needs for this new technology include the biocompatibility of nanotechnology materials, prevention of bacterial attachment to medical devices and controlled release coatings for drug-eluting stents.

Medical device coatings is a $5 billion-a-year industry1. This high-growth market is driven by advances in technology and represents a significant opportunity for AeonClad's plasma deposition technology.

AeonClad Coatings Chief Scientist Dr. Timmons‘ pioneering research spans more than 40 years and has encompassed surface chemistry, chemistry of plasma systems, catalysis, coatings technology, photochemistry and chemistry kinetics, with applications in environmental, industrial and medical diagnostics.

In addition to serving as Chief Scientist of the new company, Dr. Timmons will remain Professor of Chemistry at The University of Texas at Arlington, where he was appointed Distinguished University Professor and Member of the UTA Academy of Scholars

Tony Taylor, who also serves as Senior Vice President of Business Development for Emergent Technologies, Inc. (ETI), said, "We are excited to have such a pioneer in his field as Dr. Timmons leading our research at AeonClad Coatings. We have already identified a number of important applications in the medical and industrial markets, such as coating nano- and microbeads for improved drug delivery or filtration efficiency

ETI is a life sciences venture firm focused on selecting and funding early technology deals from universities with the goal of partnering with industry leaders to commercialize the technology. ETI's Fund IV has been established to invest in early-stage companies formed to license and commercialize technologies created by, developed by, owned by, or synergistic with institutions of The University of Texas System.

1 BCC Research - Medical Device Coatings 2006

####

About AeonClad Coatings, LLC
AeonClad Coatings is a specialty formulation company founded on the pioneering research of Dr. Richard Timmons and his team. The AeonClad Coatings plasma deposition technology offers a single-step, solvent-free process producing pinhole-free and conformable films. The technology also enables the deposition of specific functional groups on a surface to produce antimicrobial, anti-thrombogenic, lubricious, and biocompatible interfaces.

About Emergent Technologies, Inc.

Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region. For more information, visit the company website http://www.etibio.com .

For more information, please click here

Contacts:
AeonClad Coatings Contact:
Tony Taylor, 512-697-8223
Managing Director

or
Media Contact:
Nsight Public Relations
Sandra Oak, 321-591-1508

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Materials/Metamaterials

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

Nanotechnology Improves Quality of Anti-Corrosive Coatings October 17th, 2014

Graphenea opens US branch October 16th, 2014

Announcements

Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014

Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014

Nitrogen Doped Graphene Characterized by Iranian, Russian, German Scientists October 21st, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

Patents/IP/Tech Transfer/Licensing

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

‘Small’ transformation yields big changes September 16th, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE